Interview with Jan Slob, President, Akrikhin
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
Address: 52, bld 5, Kosmodamianskaya Naberezhnaya,Moscow, Russia, 115054,Russia
Tel: + 7 (495) 721 36 97
AKRIKHIN founded in 1936, is one of the leading Russian pharmaceutical producer of high-quality medicines on the Russian pharmaceutical market. By 2010 results AKRIKHIN is the 5th largest local producer by revenue and production volume on the Russian pharmaceutical market.
AKRIKHIN product portfolio counts more than 150 products focused within strategically selected Anatomo Therapeutic Classes including cardiovascular, neurology, dermatology, gynecology, pediatrics. AKRIKHIN produces a wide range of socially important medications thus making a tangible input into the development of the Russian healthcare system. AKRIKHIN is a major Russian producer of Essential Drugs which account up to 70% share of the Company product portfolio. Special emphasis is made on strategic directions of high social value – production of drugs for diabetes and tuberculosis treatment.
With the Company Field Force operating in 76 cities all across Russia and highly professional marketing team AKRIKHIN has succeeded in forming a wide and well-diversified product portfolio well recognized by doctors.
AKRIKHIN production facilities is a consolidated GMP-oriented complex located 30 km from Moscow with the workshops for production of a vast spectre of drug forms: tablets, capsules, ointments, gels, creams, syrups, etc. AKRIKHIN production existing capacities amount to more than 50 mln packs per year.
Starting from 2007 AKRIKHIN entered a strategic alliance with Polpharma – the largest Polish manufacturer of generic drugs and pharmaceutical substances. AKRIKHIN and Polpharma strategic partnership embracesincorporates common product portfolio, production technologies transfer, R&D cooperation, access to best European practices and standards, joint educational programmes for personnel.
In the “Rating of influence of Russian pharmaceutical market participants” based on pharmaceutical market experts’ opinions “AKRIKHIN” is included into the TOP 3 most authoritative and influential Russian pharmaceutical producers upon the results of 2010.
AKRIKHIN priding on its 75-years’ history and traditions builds on its successful performance on the Russian pharmaceutical market, dynamically adapting itself to modern business practices and technologies.
In its portfolio of more than 150 products of various dosage forms: tablets, capsules, creams, suppositories, creams, syrups. Akrihin focuses on therapeutic areas with high social importance, ie most sought-after Russian health care system: cardiology, diabetes, neurology, dermatology, tuberculosis, gynecology and pediatrics
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here